NEW YORK (GenomeWeb) – MyCartis announced today that it has signed a deal to have the microfluidic assay cartridges for its Evaluation multiplex biomarker analysis platform manufactured at Sony DADC Biosciences' facility in Salzburg, Austria.
MyCartis, a joint venture of Biocartis and Pronota, was launched in late 2014. The Evaluation platform is intended for simultaneous analysis of multiple protein and nucleic acid markers.
Under the newly announced agreement, Sony DADC BioSciences will manufacture the cartridges for use in clinical and pharmaceutical research applications at its Salzburg, Austria facility. Specific terms of the arrangement were not disclosed.
"The collaboration between the two companies brings together a broad range of knowledge and experience," MyCartis CEO Joris Schuurmans said in a statement.
"From a manufacturing perspective, the project enhances our capabilities in both injection molding and bonding of microfluidic consumables in microtiter plate format — the de facto industry standard," added Werner Balika, engineering manager at Sony DADC BioSciences.